By far the biggest riser in the FTSE 250 at the end of last week was Dechra Pharmaceuticals (LSE:DPH). On Friday alone the share price jumped by 33%, to close at 3,704p. Yet given the reason behind the surge, I don’t see any real value in long-term investors buying the UK stock. Here’s why I’ve got that conviction.
Fading pandemic momentum
Before we get into the jump, it’s important for investors to understand what position Dechra is in. The company develops and make veterinary products, ranging from aesthetics to nutritional products.
The business has been operating for many years and it performed very well during much of 2020 and 2021. The pandemic meant that we all spent more time at home with our pets. So the general demand for Dechra products increased over this period.
This has fallen off as we’ve emerged on the other side of the pandemic. In fact, in the half-year earnings report in February, operating profit dropped by 27.2% versus the same period in its prior year. It also warned that full-year operating profit would be at the lower end of current expectations.
Given the performance over the past few months, it wasn’t surprising that the stock was down 38% over the past year (before the move on Friday).
An offer in the works
The reason for the jump was news breaking of discussions of a buyout from private equity firm EQT Partners. Whenever chatter of an offer comes through, one of the key points for investors is what the offer price would work out to be. In this case, it’s 4,070p.
Historically, when this sort of news comes out, we see a jump in the stock close to where the offer price is set. It won’t usually hit the exact price because there’s always some uncertainty about whether a deal will go through.
This was the case for the stock on Friday, as it jumped to 3,700p, not a million miles away from 4,070p. The difference in price makes sense, as EQT Partners has until the second week of May to put a firm offer on the table. Developments over the coming weeks should help dictate if an agreement going to be successful.
Why I’m not interested in buying
Without the talk of an offer, I wouldn’t be bothered at all about buying Dechra Pharmaceuticals shares based on the current financial outlook. So to consider buying now would simply be due to the offer. Yet at 3,700p, the best case is a 10% move higher to the likely offer price. On the other hand, if the whole thing falls through, there’s significant risk of a sharp move lower (maybe 30%-40%).
This kind of risk/reward ratio just isn’t something I feel smart investors should be contemplating. It’s a short-term coin toss rather than a long-term fundamentally driven investment choice. As a result, I think this is a story that investors should keep an eye on, but nothing more.
The post This UK stock jumped 33% on Friday, but I’m not touching it! appeared first on The Motley Fool UK.
5 stocks for trying to build wealth after 50
Inflation recently hit 40-year highs… the ‘cost of living crisis’ rumbles on… the prospect of a new Cold War with Russia and China looms large, while the global economy could be teetering on the brink of recession.
Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.
Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…
We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.
Claim your free copy now
setButtonColorDefaults(“#5FA85D”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#43A24A”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#ffffff”, ‘color’, ‘#FFFFFF’);
})()
More reading
Why is the Dechra Pharmaceuticals share price soaring?
Jon Smith has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.